PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34127944-0	2021	Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling.	avasimibe	0-9	aldo-keto reductase family 1 member C1	Homo sapiens	69-75	
30774369-0	2019	Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma.	avasimibe	0-9	aldo-keto reductase family 1 member C1	Homo sapiens	51-57	
30774369-6	2019	Avasimibe was found to inhibit cell proliferation and tumor growth by reducing the expression of AKR1C1 and FoxM1 in vivo and in vitro.	avasimibe	0-9	aldo-keto reductase family 1 member C1	Homo sapiens	97-103	
34127944-2	2021	In the study, we proved that avasimibe retard cell proliferation and tumor growth of CCAs and identified FoxM1/AKR1C1 axis as the potential novel targets of avasimibe.	avasimibe	157-166	aldo-keto reductase family 1 member C1	Homo sapiens	111-117	
34127944-9	2021	Our study demonstrates a novel positive regulatory between FoxM1 and AKR1C1 contributing cell growth and tumor progression of CCA and avasimibe may be an alternative therapeutic option for CCA by targeting this FoxM1/AKR1C1 signaling pathway.	avasimibe	134-143	aldo-keto reductase family 1 member C1	Homo sapiens	69-75	
34127944-9	2021	Our study demonstrates a novel positive regulatory between FoxM1 and AKR1C1 contributing cell growth and tumor progression of CCA and avasimibe may be an alternative therapeutic option for CCA by targeting this FoxM1/AKR1C1 signaling pathway.	avasimibe	134-143	aldo-keto reductase family 1 member C1	Homo sapiens	217-223